BrightPath Biotherapeutics
FDA Grants Priority Review to Boehringer's Zongertinib for HER2-Mutant Advanced Lung Cancer
• Boehringer Ingelheim's zongertinib could become the first oral targeted therapy for previously treated HER2-mutant advanced non-small cell lung cancer, with FDA decision expected in Q3 2025.
• Phase Ib trial demonstrated impressive 71% objective response rate in 75 previously treated NSCLC patients, with favorable safety profile and low treatment discontinuation rate.
• The drug addresses a significant unmet need in HER2-mutant NSCLC patients, who currently face poor prognosis with limited treatment options and less than 30% five-year survival rate.
CD39-Targeted Therapies Show Promise in Modulating Immune Responses Across Multiple Diseases
• CD39-targeted therapies are emerging as a promising strategy to modulate immune responses in various diseases by influencing the purinergic signaling pathway.
• Inhibition of CD39 activity may restore immune functionality and improve patient outcomes in oncology, chronic viral infections, autoimmune disorders, and sepsis.
• Several CD39-targeting therapies are progressing through clinical trials, with IPH5201 being a leading candidate showing encouraging outcomes in early-phase investigations.
• The integration of anti-CD39 antibodies with other treatments may offer synergistic effects, but challenges remain in balancing immune activation and suppression.
© Copyright 2025. All Rights Reserved by MedPath